Leukemia Steering Committee

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

The NCI Leukemia Steering Committee (LKSC) was established in 2009. At monthly meetings, it addresses the design, prioritization, and evaluation of concepts for phase 2 and phase 3 clinical trials in adult leukemia cancer. View the LKSC member roster.

Strategic Priorities

  • LKSC Strategic Priorities were formulated with the goal that the majority of submitted concepts would align with these established priorities. They address areas of unmet clinical need, important unanswered clinical questions, and potential new approaches to disease treatment.

Clinical Trial Planning Meetings (CTPMs)

CTPMs are held periodically and focus on specific clinical trial related topics. The following are important LKSC CTPMs:

  • Acute Myelogenous Leukemia (AML) Working Group
    A series of teleconferences during 2014 and 2015 focused on development of biomarker-driven trials in AML in older patients. This effort culminated in two in person meetings in December, 2015 and June, 2016 to achieve consensus on the details of trial design. Read the executive summary.
  • Minimal Residual Disease in Adult Leukemia
    Minimal residual disease (MRD) is the leukemic cells remaining in the blood after initial treatment for leukemia measured by either flow cytometry or DNA-based methods. It is an important prognostic tool but requires standardization for use in clinical trials. Two workshops were held in 2012 to address standardization. Read the executive summary.
  • Acute Lymphocytic Leukemia (ALL)
    In November 2011, a CTPM was convened to discuss ALL treatment strategies, consider trials for disease subtypes, and obtain a general consensus on the next clinical trials to be conducted by NCI. Read the executive summary.
  • Chronic Lymphocytic Leukemia (CLL) Working Group
    In November 2010, a CTPM was convened to discuss current and prospective clinical trials and correlative sciences that will improve the treatment of CLL. Read the executive summary.

Contact

For more information, contact Lawrence Baizer, Ph.D. at baizerl@mail.nih.gov.

  • Updated: December 14, 2016